contact us > site map > search
 © 2006-2008 Gloucester Pharmaceuticals All rights reserved. | Privacy policy | Terms | Contact Us | Site Map |


01/28/2008
Gloucester Pharmaceuticals Announces New Senior Management Team
[View Press Release]
12/10/2007
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Pivotal Trial of Romidepsin for Cutaneous T-cell Lymphoma at the 2007 ASH Annual Meeting
[View Press Release]
12/10/2007
Gloucester Pharmaceuticals Announces Positive Interim Results of Phase I/II Study in Patients with Multiple Myeloma at the 2007 ASH Annual Meeting
[View Press Release]
Gloucester's lead compound, romidepsin (depsipeptide) is currently being evaluated in two separate multi-national pivotal trials, one for the treatment of cutaneous T-cell lymphoma (CTCL) and one for the treatment of peripheral T-cell lymphoma (PTCL).